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Background. Few studies have explored how providers communicate about control medications during pediatric asthma visits.
Objectives. The purpose of this study was to: (a) describe the extent to which providers discuss, educate, and ask children and their
caregivers questions about control medications and (b) examine how child, caregiver, and provider characteristics are associated
with provider communication about control medications during pediatric asthma visits. Methods. Children ages 8 through 16
with mild, moderate, or severe persistent asthma and their caregivers were recruited at ﬁve pediatric practices in nonurban areas
of North Carolina. After audio-tape recording medical visits, caregivers completed questionnaires and children were interviewed.
Generalized estimating equations were used to analyze the data. Results. Providers educated families about control medications
during 61% of the visits, and they asked questions about control medications during 67% of visits. Providers were signiﬁcantly
more likely to discuss control medications if a child was taking a control medication, if the child had moderate to severe persistent
asthma, and if the child was present for an asthma-related visit. Conclusion. Providers need to educate and ask more questions of
families about side eﬀects and how well control medications are working.
1.Introduction
Asthma aﬀects an estimated 8.9% of USA children under 17
years and continues to be one of the most common child-
hoodchronicillnesses[1].Uncontrolledasthmaisassociated
with more school days missed among children, more work
days missed among caregivers, and poorer quality of life
among both [2, 3]. A special case of poor asthma control,
nighttime awakenings from asthma, have been linked to
school absences, lower school performance, and parents’ lost
workdays [4]. One factor that explains uncontrolled asthma
is poor medication adherence [5].
The National Heart, Lung, and Blood Institute (NHLBI)
guidelines provide several recommendations for proper
asthma management to minimize uncontrolled asthma.
These guidelines include: use of pharmacologic therapy,
patient education, reduce environmental triggers, and assess
and monitor asthma control [6]. The guidelines emphasize
the importance of using a collaborative approach between
providers, parents, and children to develop an appropriate
asthma management plan for the child. However, recent
studies have found that these guidelines are not being
met, with less than half of families ever receiving any
education about their child’s asthma [7, 8]. In another study,2 International Journal of Pediatrics
most hospitalizations for asthma attacks were found to be
preventable and had medications been taken regularly [9].
Prior research indicates that asthma patients who report
poor communication with their physicians are less adherent
with inhaled steroids [10, 11].
Few studies have examined how physicians communicate
about medications during medical visits using actual com-
munication data and to our knowledge, no prior study has
investigated how physicians communication about control
medicationsduringpediatricasthmavisits[12–15].Findings
from these prior adult studies suggest that communication
about medications can be improved. In a sample of 40
Veterans who were on continued or newly prescribed antide-
pressants, providers asked 6% of patients about adverse
eventsand15%ofpatientshowwelltheantidepressantswere
working. Moreover, providers only gave 10% of patients’
information about adverse events and 5% information on
how well the medication works [13]. Young et al. [14] used
standardized patients (n = 131) and found that physicians
provided information about side eﬀects to 85% of patients
but only gave information about how well the drug works to
38% of patients.
To our knowledge, there are no studies that have exa-
mined how providers communicate about control med-
ications during pediatric asthma visits. It is important
to better understand how providers communicate about
controlmedicationsduringmedicalvisitsbecausetheclinical
practice guidelines of the National Asthma Education and
Prevention Program of NHLBI encourage physicians to
discuss medications with patients at every follow-up asthma
visit [6]. Therefore, the purpose of this study was to: (a)
describe the extent to which providers discuss, educate,
and ask children and their caregivers questions about
control medications and (b) examine how child, caregiver,
and provider characteristics are associated with provider
communication about control medications during pediatric
asthma visits.
2. Methods
2.1. Participants. The study was approved by the University
of North Carolina Institutional Review Board. Providers
were recruited at ﬁve pediatric practices in nonurban areas
of North Carolina, and consent was obtained. Children
and their caregivers of these participating providers were
recruited. Children were eligible if they: (a) were ages 8
through 16 years, (b) were able to speak English, (c) could
read the assent form, (d) had been seen at the clinic at
least once before, (e) were present at the visit with an adult
caregiver (parent or legal guardian) who could read and
speak English and who was at least 18 years of age, and (f)
had mild, moderate, or severe persistent asthma. Persistent
asthma was deﬁned as experiencing asthma-related daytime
symptomsmorethantwiceaweek,asthma-relatednighttime
symptoms more than twice a month, or receiving one or
more long-term control therapies for asthma [16, 17].
Clinic staﬀ referred potentially eligible and inter-
ested patients to a research assistant who explained the
study, obtained caregiver consent and child assent, and
administered the eligibility screener. Providers and families
were told that the study was examining communication dur-
ing pediatric visits. All of the medical visits were audio-tape
recorded. Children were interviewed after their medical vis-
its. Caregivers completed self-administered questionnaires.
2.2. Audio-Tape Coding. All of the medical visit audio-tapes
were transcribed verbatim, and a detailed coding tool was
developed to assess provider communication behaviors. This
tool was reﬁned and tested over a one-year period. All of
the transcripts were coded using the coding tool and more
detail about the types of communication behaviors coded is
provided below.
2.3. Measures
2.3.1. Demographic and Sociodemographic Characteristics.
Medication use was assessed on the caregiver screener.
The research assistants showed caregivers a list of asthma
medications and asked them to indicate which one(s) the
child was taking. Responses were dichotomized based on
whether the caregiver reported that the child was taking a
control medication versus not taking a control medication.
Asthmaseveritywasclassiﬁedasmildversusmoderate/severe
by a research assistant based on recent symptoms and
medication use reported by the caregivers when research
assistants administered the eligibility screening instrument
for the study [16, 17]. Our eligibility screening instrument
utilizedtheprimaryasthmaseverityclassiﬁcationsystemthat
was being used when the study was designed and conducted
[16, 17].
All child study information was then reviewed by
a pediatric pulmonologist or a clinical pharmacist with
expertise in asthma to verify the severity classiﬁcation as
mild or moderate/severe persistent asthma. Severity was
classiﬁed using two diﬀerent methods. The ﬁrst method
was medication use; any child receiving a single long-term
control agent was considered to have mild persistent asthma.
Any child receiving two or more long-term control agents
was categorized as having moderate to severe persistent
asthma. A long-term control medicine included inhaled cor-
ticosteroids, leukotriene modiﬁers, cromolyn, nedocromil,
oralong-actingbetaagonistasdeﬁnedbytheNationalHeart
Lung and Blood Insititute’s guidelines [16, 17].
Thesecondmethod classiﬁedseveritybasedonsymptom
frequency. Subjects who reported the occurrence of any one
of eight symptoms as occurring two or more times per week
or who reported awakening with asthma symptoms two or
more times per month was classiﬁed as mild persistent. The
eight daytime symptoms included: wheezing with a cold,
wheezing without a cold, attack of wheezing that made it
hardtobreathorcatchbreaththatlastedlongerthanadayor
more, had a cough that would not go away, complained that
chest felt tight or heavy, used rescue inhaler for symptoms,
wheezed with exercise or running or playing hard, and
coughed with exercise or running or playing hard. The
nighttime symptoms asked about how often the child’s sleep
has been disturbed because of wheezing, coughing, chest
tightness, or shortness of breath. Reports of daily symptomInternational Journal of Pediatrics 3
occurrence or awakening ≥5 times a month resulted in a
classiﬁcation as moderate or severe persistent. In situations
where the two methods (medication use and symptom
frequency) resulted in discordant classiﬁcation, the more
severe category was used.
A variety of demographic factors were examined as
potential confounders. Child and caregiver age, caregiver
education, and years the child had asthma were measured
as continuous variables. Child and caregiver gender were
also measured. For descriptive purposes, child race was
recoded into four categories: White, African American,
Native American/American Indian, or Other (includes cate-
goriesof:Hispanic,AsianAmerican,other).However,forthe
bivariateanalyses,childracewasrecodedintoadichotomous
variable (White versus non-White). The child’s insurance
status was measured using the following categories: none,
private insurance, Medicaid, the State Children’s Health
Insurance Program (SCHIP), and others. How well the
child thinks the provider knows them as a person was
measured with the following categories: hardly at all, slightly,
moderatelywell,andverywell.Reasonforvisitwasmeasured
as asthma-related versus other (e.g. physical). Length of
visit was measured in minutes, and whether the child was
taking a control medication was measured as a dichotomous
variable.
2.3.2. Provider Discussion, Education, and Question-Asking
about Control Medications. All of the medical visits audio-
tapes were transcribed verbatim. A detailed coding tool was
developed over a one-year period. The categories used in the
coding tool for communication about asthma medications
were adapted from the categories used in prior studies of
provider-patient communication about medications [12–
15]. The transcripts were reviewed by two research assistants
who met twice a month with the investigators to develop and
reﬁne the coding rules until themes were saturated.
Using the coding tool for transcribed medical visits,
coders recorded the following: was there any discussion of
control medications, did the provider give any education
about control medications, and how many questions did the
provider ask the child and caregiver about control medica-
tions. The research assistants then coded whether discussion,
education, and question-asking occurred in each of the fol-
lowing areas: adherence, fears/concerns, frequency/timing,
generic/brand, how well it works, purpose, side eﬀects,
strength/dose, supply, and others. Two research assistants
coded 20 of the same transcripts throughout the study
period to assess intercoder reliability which was calculated
using interrater correlations. Inter-rater reliability was 1.0
for whether control medications were discussed, 0.87 for the
number of areas discussed, 0.91 for whether the provider
educated about control medications, 0.80 for number of
areas the provider educated about, and 0.95 for the number
of questions the provider asked about control medications.
2.3.3. Statistical Analysis. All analyses were conducted using
SPSS v. 14. All children were included in the analyses because
even if children were not on a control medication, control
medications could have been discussed during the visit as
a possible treatment. First, we present descriptive statistics
for the demographic, clinical, and provider communica-
tion variables. Second, we examine bivariate relationships
between the demographic variables and provider commu-
nication variables using correlation coeﬃcients, t-tests, or
Pearson chi-square statistics, as appropriate.
Next, we used generalized estimating equations (GEE)
to examine how demographic and clinical characteristics of
the child and caregiver were associated with: (a) whether
the provider discusses control medications, (b) whether the
provider educates about control medications, and (c) how
manyquestionstheproviderasksaboutcontrolmedications.
All generalized estimating equations were clustered on
provider. A Poisson GEE was used to examine provider
question-asking because the variable was skewed.
3. Results
3.1. Sample Characteristics. The ﬁve participating clinics
wereallprimarycarepediatricpractices.Forty-oneproviders
agreed to participate in the study; two providers refused
to participate for a participation rate of 95.3%. Providers
completed a short demographic questionnaire after pro-
viding consent. Three hundred and thirty-three of the 377
families (88%) that approached the research assistant to
learn more about the study agreed to participate in the
study. Two-hundred and ninety six patients of the 333
participating patients (89%) had useable audio-tape data,
and these patients were seen by 35 of the 41 providers who
agreed to participate in the study. Four of the 35 providers
were nurse practitioners or physician assistants, and they saw
seventeen of the participating children. Fifty-one percent of
the providers were female. Twenty-seven of the providers
were White, two were American Indian, three were African
American, one was Asian, and two classiﬁed their race as
other. Providers ranged in age from 30 to 70 years (mean =
44.8 years, standard deviation = 9.4).
Table 1 presents the child and caregiver demographic
characteristics. Forty-six percent of the children were female.
The average age of the children was 11 years. Approximately
62%ofthechildrenwereWhite,30%wereAfricanAmerican,
and 10% were Native American/American Indian. In terms
of the child’s asthma, caregivers reported that their children
had asthma for an average of six years. Seventy-two percent
of these children had moderate to severe persistent asthma.
Only three families in the sample did not have health
insurance. Eighty-three percent of patients were on a control
medication.
3.2. Provider Discussion, Education, and
Question-Asking about Control Medications
3.2.1. Control Medication Discussion. Providers discussed
control medications during 83.4% of encounters. Providers
discussed control medications during 87.4% of visits where
children were taking control medications and during 63.8%
of visits where children were not taking control medications.
The average number of topic areas discussed was 2.92
(standard deviation = 2.0; range 0 to 8 areas). Table 2 shows4 International Journal of Pediatrics
Table 1: Child and caregiver demographic characteristics (N =
296).
Percent (N)
Child Age
Mean (SD) Range 11.1 (2.4) 8–16
years
Child Gender
Male 53.7 (159)
Female 46.3 (137)
Child Race
White 61.5 (182)
African American 30.1 (89)
Native American/American Indian 10.1 (30)
Other 6.1 (18)
Asthma Severity
Mild persistent 28.0 (83)
Moderate/Severe persistent 72.0 (213)
Number of years living with asthma
Mean (SD) Range 6.0 (3.9) 9–16
years
Caregiver relationship status
Never 16.2 (48)
Married 57.8 (171)
Separated 9.5 (28)
Divorced 12.5 (37)
Widowed 3.0 (9)
Caregiver Age
Mean (SD) Range 42.0 (8.4) 27–81
years
Caregiver Gender
Male 14.2 (42)
Female 85.8 (253)
Caregiver Education in Years
Mean (SD) Range 12.8 (2.5) 2–20
years
Reason for Visit
Asthma related 51.4 (152)
Other 48.7 (144)
Insurance Type
None 1.0 (3)
Private 26.4 (78)
Medicaid 51.7 (153)
State Children’s Health Insurance Program 51.7 (153)
Other 2.7 (8)
Reason for Visit
Asthma related 51.4 (152)
Non-asthma related 48.6 (144)
the control medication areas that providers discussed most
often during the medical visits: (a) frequency/timing of use
(63%), (b) supply of medication (50%), (c) strength/dose of
medication (48%), (d) adherence (47%), and (e) purpose
of the controller medication (34%). Side eﬀects were only
discussed during approximately 11% of encounters and
fears/concerns were only discussed during 4.4% of encoun-
ters.
In the bivariate results, control mediations were signiﬁ-
cantly more likely to be discussed if a child was on a control
medication (Pearson chi-square = 16.1, P<0.001), if the
child had moderate/severe persistent asthma (Pearson chi-
square = 12.8, P<0.001), and if the child was present for an
asthma-related visit (Pearson chi-square = 14.48, P<0.001).
Table 3 presents the GEE results predicting provider dis-
cussion of control medications. Providers were signiﬁcantly
more likely to discuss control medications if a child was on a
control medication and during visits with children who had
moderate to severe persistent asthma compared to children
with mild persistent asthma. Providers were also more likely
to discuss control medications when the reason for visit was
asthma-related versus not asthma-asthma-related.
3.2.2. Control Medication Education. Providers educated
about control medications during 61.1% of encounters. The
average number of areas educated about was 1.54 (standard
deviation = 1.6; range 0 to 7 areas). As presented in Table 2,
providers educated about control medications most often
in the following areas: (a) frequency/timing of use (37%),
(b) strength/dose (32%), and (c) purpose (30%). Providers
educatedaboutsideeﬀectsduringonly7%ofencountersand
how well it works during only 8% of encounters. Providers
were signiﬁcantly more likely to provide education about
control medication side eﬀects if a child was not on a control
medication (Pearson chi-square = 5.1, P = 0.02).
In the bivariate results, providers were more likely
to educate about control medications if the child had
moderate/severe persistent asthma (pearson chi-square =
13.3, P< 0.001), if the child was younger (t-test = −2.71,
P = 0.007),andifthechildwaspresentforanasthma-related
visit (Pearson chi-square = 12.9, P<0.001).
Table 3 demonstrates which child and caregiver charac-
teristics were associated with whether providers educated
families about control medications. Providers were signif-
icantly more likely to educate about control medications
during visits with children who had moderate to severe
persistent asthma, younger children, and during visits that
were primarily asthma-related.
3.2.3. Control Medication Question Asking. Providers asked
one or more questions about control medications during
66.6%ofencounters.Theaveragenumberofquestionsasked
was 2.68 (standard deviation = 3.1; range 0 to 16 questions).
Providersweremostlikelytoaskchildrenandtheircaregivers
questions about control medications in the following areas:
(a) frequency/timing of use (38%), (b) adherence (37%),
and (c) supply (29%). Providers only asked about side
eﬀects during 2% of encounters, fears/concerns during 1%
of encounters, and how well the control medications were
working during approximately 12% of encounters (Table 2).
In the bivariate results, providers were more likely to ask
control medication questions if the child was on a controlInternational Journal of Pediatrics 5
Table 2: Communication about control medications during pediatric asthma visits (N = 296).
Any discussion Any education Any question asking
Percent (N) Percent (N) Percent (N)
Adherence 46.6 (138) 16.9 (50) 37.2 (110)
Fears/Concerns 4.4 (13) 3.4 (10) 1.0 (3)
Frequency/Timing 63.2 (187) 37.5 (111) 38.2 (113)
Generic/Brand 0 (0) 0 (0) 0 (0)
How well it works 22.6 (67) 7.8 (23) 11.8 (35)
Purpose 34.1 (101) 30.1 (89) 1.7 (5)
Side eﬀects 10.8 (32) 7.1 (21) 1.7 (5)
Strength/Dose 47.6 (141) 32.1 (95) 22.3 (66)
Supply 50.0 (140) 13.5 (40) 29.4 (87)
Other 13.5 (40) 3.4 (19) 10.1 (30)
Table 3: Generalized estimating equation results predicting provider discussion of and education about control medications (N = 296).
Independent variables Any discussion Any education
OR (95% CI) OR (95% CI)
Child’s severity of asthma, moderate severe 2.87 (1.69, 4.87)∗∗∗ 2.30 (1.58, 3.34)∗∗∗
Years living with asthma 1.00 (1.00, 1.00) 1.00 (1.00, 1.00)
Taking a control medication 3.35 (1.59, 7.08)∗∗ 1.23 (0.53, 2.87)
Child age in years 0.90 (0.75, 1.08) 0.87 (0.79, 0.96)∗∗
Child gender, female 0.58 (0.30, 1.12) 0.85 (0.54, 1.33)
Child race, White 1.37 (0.54, 3.47) 1.16 (0.57, 2.36)
How well child feels provider knows them as a person 0.90 (0.60, 1.36) 0.92 (0.73, 1.17)
Caregiver years of education 1.04 (0.90, 1.22) 1.02 (0.92, 1.13)
Provider race, White 1.71 (0.51, 5.82) 1.36 (0.53, 3.47)
Provider age 0.99 (0.93, 1.04) 1.00 (0.96, 1.30)
Provider gender, female 0.85 (0.31, 2.35) 0.70 (0.27, 1.84)
Length of visit 1.00 (1.00, 1.00) 1.00 (1.00, 1.00)
Reason for visit, asthma related 3.66 (2.05, 6.53)∗∗∗ 2.33 (1.52, 3.58)∗∗∗
∗∗P<. 01, ∗∗∗P<. 001.
medication (t-test = 3.5, P = 0.001) and if the child was
younger (Pearson correlation coeﬃcient = −0.12, P = 0.04).
Table 4 presents the Poisson GEE results predicting
the number of questions providers asked about control
medications. Providers asked more questions about control
medications if a child was currently treated with a control
medication. Providers also were more likely to ask younger
children more questions about control medications than
older children.
4. Discussion
Providers discussed the frequency of use, supply of medi-
cation, and strength/dose of medication with families most
often, but they only discussed the purpose of the control
medication during about one third of all visits and how well
the medication works during about a quarter of all visits.
Providers rarely discussed side eﬀects and fears/concerns
about control medications. According to clinical practice
guidelines of the National Asthma Education and Prevention
Program of NHLBI, it is important for providers to discuss
these areas with patients [6].
The national clinical practice guidelines instruct pro-
viders to teach and reinforce the roles of control medications
at every opportunity [6], yet providers in this study only
educated children and their caregivers about control medi-
cations during about two-thirds of the visits. Providers need
to give more education about control medications during
pediatric asthma visits. It is especially critical for families
to understand the purpose of asthma control medications
so that they understand the diﬀerence between control and
rescue medications.
Providers rarely educated about side eﬀects and how well
the medications work even though according to the practice
guidelines of the National Asthma Education and Prevention
Program of NHLBI, providers should ask about speciﬁc side
eﬀectsfromcontrolmedicationsduringroutineasthmavisits
[6]. Our results provide evidence that discussion of asthma
controllermedicationdoesnotoccurateveryfollow-upvisit.
Given recent evidence that poorly controlled asthma
(56%) is common among children receiving asthma care
from community pediatricians [18], this study points
to provider discussion and education as a key area for6 International Journal of Pediatrics
Table 4: Poisson generalized estimating equation results predicting
the number of questions providers ask about control medications
(N = 296).
Independent variables β (95% CI)
Child’s severity of asthma, moderate severe 0.19 (−0.32, 0.70)
Years living with asthma 0.00 (−0.00, 0.00)
Taking a control medication 1.15 (0.22, 2.07)∗
Child age in years 0.19 (0.10, 0.29)∗∗∗
Child gender, female 0.39 (−0.12, 0.89)
Child race, White −0.41 (−0.83, 0.01)
How well child feels provider knows them as
ap e r s o n 0.06 (−0.14, 0.25)
C a r e g i v e ry e a r so fe d u c a t i o n 0 . 0 1( −0.10, 0.13)
Provider race, White 0.17 (−0.61, 0.95)
Provider age −0.02 (−0.06, 0.01)
Provider gender, female −0.36 (−1.02, 0.30)
Length of visit 0.00 (−0.00, 0.00)
Reason for visit, asthma related 0.00 (−0.00, 0.00)
∗P<. 05, ∗∗∗P<. 001.
improvement. If children and their caregivers better under-
stand what to expect when taking the medications, they
might be more adherent. Better adherence could lead to
improved asthma control [6] and fewer school days missed
forchildrenandreducedhealthcarecosts[2,3].Futurework
needs to assess the relationship between provider education
about control medications and medication adherence and
asthma control.
Communication about control medications was not
associated with any provider demographic characteristics.
However, there were certain child characteristics that were
associated with communication. Speciﬁcally, providers were
more likely to educate younger children about control
medications and they were more likely to ask younger
children more questions about control medications. Perhaps
this is because younger children are less likely to volunteer
information about their use and experiences in using control
medications. It is important to make sure that children of
all ages understand how to use their control medications.
Providers also were more likely to engage children with more
severe asthma in discussions about controller medications.
Providers asked about adherence during less than 40%
of the visits. It is important for providers to ask about
child adherence to control medications so they can work
with families to improve adherence and asthma control.
Providersaskedfewquestionsaboutsideeﬀectsandhowwell
the control medications were working, which is similar to
ﬁndings of medication communication in adults with other
medical conditions [12, 13] .I fp r o v i d e r sw a n tt od e t e c ta n d
prevent problems with asthma control medication use and
adherence, they should consider asking at least one open-
ended question about how the medications are working
and a second question about any side eﬀects or barriers
to use (e.g., “How are your asthma medications working?”
and “What types of problems have you had with your
medications?”).
The study’s generalizability is limited in that it was
conducted in ﬁve pediatric clinics in nonurban areas of
NorthCarolina.Anotherlimitationisthatclinicstaﬀreferred
potentially eligible patients to the research assistant; thus, we
do not know how many referred patients chose not to talk
with the research assistant. However, we could not ask the
clinic staﬀ to track these numbers because of the busyness
of the clinic and our promise not to interrupt clinic ﬂow.
Providers and caregivers knew they were being recorded and
may have changed their communication, but they did not
know the study hypotheses. It is also important to note that
we did not assess the level of control in this study based
on the current NHLBI guidelines [6] because this study was
initiated prior to the release of the new guidelines. Another
limitation is that we did not include children ages 2–7 years
and adolescents ages 17-18 years. Future research should
examine provider discussion, education, and question-
asking about control medications in these age groups.
Despiteitslimitations,thisstudypresentsinformationonthe
extent to which providers discuss and educate children about
control medications during pediatric medical visits.
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